Portable, wireless medical devices with swallowable BioNanoSensors for gastric fluid analysis.
Erib AG, Ltd., S.A., S.p.A. (Erib Corp., Schweiz)
Hinterkappelen (CH-3032), Canton of BernNew on Amplifa
About Erib Corp.
Erib Corp. is a Swiss BioNanoMedtech and pharmaceutical company from the Canton of Bern. The company researches, develops, manufactures and distributes microtechnical, sensor-controlled medical devices for home use, in particular the portable wireless devices BMI-Watch® and WeLoxx®. These combine the function of a conventional wristwatch with monitoring of the chewing process and combinable swallowable BioNanoSensors that analyze gastric fluid and transmit data via wireless connection to the medical device. The data is stored in the device, graphically processed via software on smartphones, USB or laptop, and used for diagnostics. Key application areas are weight reduction, eating disorders and support for people with type 2 diabetes. Erib licenses its technology, based on the patents CH684982 and CH706255 (A2) as well as further applications, to pharmaceutical and insurance service providers. The location is Hinterkappelen near Bern.
- Site
- CH-3032 Hinterkappelen
- Processes
- Research & Development, Manufacturing and distribution of microtechnical medical devices for home use, Licensing of the technology to pharmaceutical and insurance customers, Analysis & diagnostics (gastric fluid analysis with BioNanoSensors)
- Materials
- Swallowable BioNanoSensors, BioStom® technology
- Certificates
- CE approval, FDA clearance, EU GDPR compliance
- Industries
- Medical technology, Biotechnology, Pharmaceuticals, Digital Health / Wearables, Weight management / Type 2 diabetes
- 01
Research & Development
- 02
Development of microtechnical sensor-controlled medical devices
- 03
In-house manufacturing and distribution for home use
- 04
Analysis & diagnostics of gastric fluid data
- 05
Licensing of the technology to pharmaceutical and insurance providers
Technology & Analysis
Swallowable BioNanoSensors
Biological, swallowable sensors for analyzing gastric fluid via biomarkers; are destroyed after approx. 30 minutes by gastric acid (HCl).
BioStom® technology
Patented technology platform for transmitting and evaluating sensor data to the portable medical device.
Location
Hinterkappelen
CHHeadquarters
Products
Inside the production
Industries
Additional services
Regulatory & Compliance
The products have CE approval (August 2010) and FDA clearance; clinical studies are documented on clinicaltrials.gov (among others NCT00407420). The company is subject to the EU GDPR.
| Evidence | Hinterkappelen |
|---|---|
| CE approval | |
| FDA clearance | |
| EU GDPR compliance |
History
- 2008
Website copyright notice (Erib Corp., Switzerland); founding date not explicitly documented
- 2010
CE approval in August 2010
- 2011
1st study & FDA clearance; clinical study NCT00407420 (Bristol Royal Hospital, UK; Dr. Per Södersten, Karolinska Institutet)
- 2012
2nd study and FDA clearance (July 2012); 3rd patent application following CH684982 and CH706255 (A2); PCT-WO2012 application; Swiss Start-Up Award (SEF) Zurich; MedTech Investing Europe Conference Montreux
- 2013
Indiegogo campaign (CA, USA); US sales activities from 1.9.2013; launch of DnBiomed, Spain
- 2014
Participation in international investor and life science conferences, including BIO-Europe, SEMICON Europa (Grenoble), Healthtech Summit Lausanne
- 2015
EMT Summit San Francisco, Wearable Tech + Digital Health NYC, New England Venture Summit, Switzerland Global Enterprise Bern
- 2016
Participations including Bio-Europe Spring Stockholm, BioVision Lyon, MedTechInvesting Lausanne, Venture 5i Grenoble, New York Venture Summit
- 2017
RESI Redefining Early Stage Investment, San Diego
- 2018
BIONNALE Berlin, RESI Boston, Venture 5i Grenoble; GDPR implementation as of 25.05.2018
- 2022
Last documented website update